{"name":"Tempus AI","slug":"tempus","ticker":"TEM","exchange":"NASDAQ","domain":"tempus.com","description":"Tempus AI, Inc. is an American health technology company founded in 2015 by Eric Lefkofsky in Chicago, Illinois. It was established by Lefkofsky soon after his wife was diagnosed with breast cancer. Tempus uses data and artificial intelligence (AI) to create precision medicine services, including diagnostics, for oncology, cardiology, radiology, and depression. The company went public on the Nasdaq on June 14, 2024, under the ticker symbol \"TEM.\"","hq":"Chicago, IL","founded":0,"employees":"3800","ceo":"Eric Lefkofsky","sector":"AI / Precision Medicine / Genomics","stockPrice":47.9,"stockChange":1.09,"stockChangePercent":2.33,"marketCap":"$8.6B","metrics":{"revenue":1271789000,"revenueGrowth":83,"grossMargin":62.7,"rdSpend":172924000,"netIncome":-245028000,"cash":754998016,"dividendYield":0,"peRatio":-767,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-06-01","label":"OncoEMR patent cliff ($0.0B at risk)","drug":"OncoEMR","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-22","type":"earnings","headline":"Tempus AI Reports Q4 2023 Earnings","summary":"Tempus AI reported Q4 2023 earnings, with revenue growth driven by its precision medicine business.","drugName":"","sentiment":"positive"},{"date":"2023-09-12","type":"deal","headline":"Tempus AI Partners with Leading Cancer Center","summary":"Tempus AI announced a partnership with a leading cancer center to develop new precision medicine treatments.","drugName":"","sentiment":"neutral"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxQOEF2V21OU1pJMU9nbXo4dlU0TnRGTy1xT29ZQmlrT1BNaGRJS3hxMjVBc3c2U1gxR2ZGaEVYbUp1MWhBZ05UZDJoRnE3WGhfdmtkMDRLaU9fbmJ4emVrZkVMaUR1TlE4b3JYeF9ITF9vNTNxZUdNam0tT2YxbzB3VmVxYl8tTzRkcDBYNmpwWDZrc0s1Z2tWai1JSGFMOEFJM0Zray1OdmlMclE?oc=5","date":"2026-03-26","type":"pipeline","source":"The Pharma Letter","summary":"Tempus, Daiichi team up on AI models for ADC development - The Pharma Letter","headline":"Tempus, Daiichi team up on AI models for ADC development","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-25","type":"deal","source":"simplywall.st","summary":"Tempus AI Deepens Pharma Role With Daiichi Sankyo Oncology Partnership - simplywall.st","headline":"Tempus AI Deepens Pharma Role With Daiichi Sankyo Oncology Partnership","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxOanpPN0d2X3c3X0swRldfMzdUQ0FsWjdxOXFGWEc0YWVrNFpyd25VQlhMbXcyeHEyWS1ZV3psUGhBS2lUMzB2UVpnblYzMlBFMHdpSjNOcXdNNUFueTVRYnZGMVRmWVZ3QTlLQi1nY0ZSUzR6WWcyZU1aanc4b3RGTGZmZ19tME9xbHptU1lncEI?oc=5","date":"2026-03-21","type":"pipeline","source":"The Motley Fool","summary":"Want $1 Million in Retirement? Invest $10,000 in These 2 AI Stocks and Hold for 10 Years. - The Motley Fool","headline":"Want $1 Million in Retirement? Invest $10,000 in These 2 AI Stocks and Hold for 10 Years.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxPeDBreUdwVGpSTF9Qc2xleUNqeDdIcGVNdzZkZld4OE82LXc1eUUtbTdQdlNrcElOa3hxekVqNUc0RHBLTjQ1Zk5xdlFacXViSVhjUmoyRk8teGVXVjNIRDh6cFNOdnR3UmU1UDdEZ0U3Tlk3NE16eTNHU2lpYkpicnBnRTBVQl9yOHpJ?oc=5","date":"2026-03-08","type":"regulatory","source":"Yahoo Finance","summary":"Tempus AI Deepens Merck Collaboration As Pharma Demand And Losses Evolve - Yahoo Finance","headline":"Tempus AI Deepens Merck Collaboration As Pharma Demand And Losses Evolve","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxQR2EzaTVxaTcza1Y2S0ZJSDNzTFZzc3BtazlSODZfYmlER1l1blR6dk4wMUlDY0VkaHRCVWdXa0pyY1E0QlE4MGJsbkpSYjhGNHp6ZTRxYnQ3ZjdFVnZ5SWRxNDFFVldrLXZ2R2dvZVZKRkNQZGtUWTVTUXJHWXFhZ2ZHNGo3SjdJUkNITGVRMEZ1ZHVhS1ZTYkl0QURFNTYtc0JPSGtVbDRyOUNtRTk4X0t5dmxvY0E3bW43SEVfQXRWOTQ1cnc?oc=5","date":"2026-03-07","type":"deal","source":"Finviz","summary":"Tempus AI, Inc. (TEM) Announces Strategic Deal with Merck to Fast-Track AI-Driven Precision Medicine - Finviz","headline":"Tempus AI, Inc. (TEM) Announces Strategic Deal with Merck to Fast-Track AI-Driven Precision Medicine","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwJBVV95cUxNMmNUcEJWczlMRTZvcjVnOEh5cHpNWGM4RGZOb0R5VFJBa3NpMjBoZEwzX09CQ2tmVGVTQmRhWkU0R2tvMmlNRWpSLWRITnc1SWZaWlZfcHBTSkRqN0cwRUoxdFpYZmxtYXhQdWZpTjc2Z1VuYUZ0b01UR0hfQ0xDWFUxMmNqT0NaVFhlMTRKRGtIUXowa1RmMkVERmtxUXB0R01NdVRuTXBtVVEweWN5YjB6eVdaOW5nTlpQdm9JTmMzMktWazV0QURzLVZCWlZBc000TlZ0VzU2b1NLSGxkTW5CcnB2NEE5MWpNRUZJcFNUQnoyMWM4TFF1Y3hkQ1M4VE93UFNuSDc1UGNiS2xIOW1BdGIxdGFFLURiekVOQVdReUZOcUpoQm5lMGNuOTZSU29qak0za2YwV0U?oc=5","date":"2026-02-26","type":"pipeline","source":"The Globe and Mail","summary":"Analysts Offer Insights on Healthcare Companies: Tempus AI, Inc. Class A (TEM), BridgeBio Pharma (BBIO) and Establishment Labs Holdings (ESTA) - The Globe and Mail","headline":"Analysts Offer Insights on Healthcare Companies: Tempus AI, Inc. Class A (TEM), BridgeBio Pharma (BBIO) and Establishmen","sentiment":"neutral"},{"date":"2026-02-24","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-02-24","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxQMHJ4SmJmbEl3QnhYMU9kWERjRGRRQnlrQloyS1A4NDh5anAtM0kzamczaXNoRXNQclBwVmlwUVdVamwwaC12UlZLeTdGLUtzTm9jUkJreGlVOTdRUmlTWUJqTTVzY3lkWFhFS2x5TFBKSGJwaWJlbUh0NXpKV1dhQUlZN1EweU1kTGIwSmp0OFFRTGwwTjZoVzhvRXlXRlhy?oc=5","date":"2026-01-12","type":"pipeline","source":"TradingView","summary":"Tempus AI's Pharma Momentum Accelerates - TradingView","headline":"Tempus AI's Pharma Momentum Accelerates","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxOM20xeHVHR1M0eDRWZDNLdVFrVk45ME9QaEh0THBaLTVaUWFEdE8yQ2ZqaUE0eXh0VDYxeTVlQVBrVnlWY1pveHdrdVFJQjZEdkJpM1ZKUEJpTXU2SjBsMFlCaE5aR0F1S2I3LTRpcWJrdGI5R0lXcUxISWRVNDFRcW9kc1lVbWhJU2Y4N2d4cFBnamlrRjVpUTZrOW5zLURkeDEyaDEySzJkaGJzYW1aeQ?oc=5","date":"2026-01-12","type":"pipeline","source":"CoinCentral","summary":"Tempus AI (TEM) Stock: Contract Value Tops $1.1 Billion as Pharma Giants Adopt AI Platform - CoinCentral","headline":"Tempus AI (TEM) Stock: Contract Value Tops $1.1 Billion as Pharma Giants Adopt AI Platform","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiR0FVX3lxTE9qdjVYaE5KQzlOWE1zalZJRkZiaWRNTi1CWlc5MnN5dU9ZeDEwVDh2R05NdFpnNWtSUlhhOXF0SGF5RXZScXZz?oc=5","date":"2026-01-12","type":"pipeline","source":"MEXC","summary":"Tempus AI (TEM) Stock: Contract Value Tops $1.1 Billion as Pharma Giants Adopt AI Platform - MEXC","headline":"Tempus AI (TEM) Stock: Contract Value Tops $1.1 Billion as Pharma Giants Adopt AI Platform","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTE1xTmgtUEQtZVNRNXNjSWI1eWpVTHVxR0hKSG9hVHhkMkVaZjhPYVp5eEppemlmOFpETFlUTjdDWUM2NldkTnk1Z1lfeEJGTlBQYlVNbUlrcFFMa1ZT?oc=5","date":"2025-09-18","type":"trial","source":"mlq.ai","summary":"Tempus AI (TEM): At the Crossroads of Diagnostics and Data - mlq.ai","headline":"Tempus AI (TEM): At the Crossroads of Diagnostics and Data","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxPdWFGYXRtdFRmdlVPN1hmQWdHN0tqelFwOF8wd016NWctU3d0a2xFeEJfbnZBN3NHMHk4R2ZGMDNwdGJrRWlOQ3ZLQjJvRWg1VTBpY29rMDhUbjFwcTNmN3FoaFZXbXY1bWpkQXNhZ1NwUEhrTXNSWWRrdEtmUng0Sjlhc3lwVHNlTkQwUzB1VWVQSE5UMjhEOEhja1EyU0taenU3YlZpbXNtX0VjVVNfUVBMUXpPV1hSV0Jn?oc=5","date":"2025-09-04","type":"pipeline","source":"Seeking Alpha","summary":"Tempus AI: Expansive Opportunity As Healthcare Becomes More Heavily Scrutinized (TEM) - Seeking Alpha","headline":"Tempus AI: Expansive Opportunity As Healthcare Becomes More Heavily Scrutinized (TEM)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxPRXNTaTFzeEJ0QmFGelYxb3drbWNGcDlFQWJ1QXFhWGUtVUZURV9saVRUekNsZ2xaclJDeWcwMTRHRVd4Q2xhY2Q1QVI3S0daVHVLd1VRSm9xZDhpS09YR2huNFRmNE1TdmVFNlRQcm13VXZUMWZsdVZiRnoxdEtmVXAySmk3c2tTRTgzRGNFTmU2UWhvYkFlVUp0Uy1YOWx3aFJkcXFDSTc0YThvSEdLak5Kckc3OFN2eTVJcXFEaHBwa3JhRUE?oc=5","date":"2025-07-26","type":"pipeline","source":"Sahm","summary":"Palantir, Nvidia & Tempus AI Could Be Pharma ETF Darlings That Don't Make Pills - Sahm","headline":"Palantir, Nvidia & Tempus AI Could Be Pharma ETF Darlings That Don't Make Pills","sentiment":"neutral"}],"patents":[{"drugName":"OncoEMR","drugSlug":"oncoemr","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":0}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Foundation Medicine","Invitae","Guardant Health"],"therapeuticFocus":["Oncology"],"financials":{"source":"sec_edgar","revenue":1271789000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":1271789000,"period":"2025-12-31"},{"value":693398000,"period":"2024-12-31"},{"value":693398000,"period":"2024-12-31"},{"value":531822000,"period":"2023-12-31"},{"value":531822000,"period":"2023-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":172924000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-245028000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":2274838000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":47.9,"previousClose":46.81,"fiftyTwoWeekHigh":104.32,"fiftyTwoWeekLow":36.22,"fiftyTwoWeekRange":"36.22 - 104.32","fiftyDayAverage":53.24,"twoHundredDayAverage":68.16,"beta":0,"enterpriseValue":8941422592,"forwardPE":-767,"priceToBook":17.36,"priceToSales":6.73,"enterpriseToRevenue":7.03,"enterpriseToEbitda":-52.13,"pegRatio":0,"ebitda":-171512992,"ebitdaMargin":-13.5,"freeCashflow":-112498872,"operatingCashflow":-218090000,"totalDebt":1327129984,"debtToEquity":270.1,"currentRatio":3.13,"returnOnAssets":-9.7,"returnOnEquity":-89.5,"analystRating":"2.0 - Buy","recommendationKey":"buy","numberOfAnalysts":14,"targetMeanPrice":75.43,"targetHighPrice":100,"targetLowPrice":58,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":39.1,"institutionHeldPercent":55.3,"sharesOutstanding":173729901,"floatShares":113036816,"sharesShort":25090144,"shortRatio":4.48,"shortPercentOfFloat":14,"epsTrailing":-1.4,"epsForward":-0.06,"revenuePerShare":7.3,"bookValue":2.76,"officers":[{"age":55,"name":"Mr. Eric P. Lefkofsky J.D.","title":"Co-Founder, CEO, President & Chairman"},{"age":40,"name":"Mr. Ryan  Fukushima","title":"Chief Operating Officer"},{"age":51,"name":"Mr. Andrew  Polovin","title":"Executive VP, General Counsel & Secretary"},{"age":38,"name":"Mr. James  Rogers","title":"Chief Financial Officer"},{"age":42,"name":"Mr. Ryan M. Bartolucci CPA","title":"Chief Accounting Officer"},{"age":null,"name":"Mr. Shane  Colley","title":"Chief Technology Officer"},{"age":48,"name":"Dr. Kate A. Sasser Ph.D.","title":"Chief Scientific Officer"},{"age":53,"name":"Mr. Erik  Phelps","title":"Executive VP, Assistant Secretary and Chief Administrative & Legal Officer"}],"industry":"Health Information Services","irWebsite":"","website":"https://www.tempus.com","phone":"800 976 5448"}}